Tirzepatide
60 mg / 3 ml · Injectable pen
Dual GIP / GLP-1 receptor agonist
Tirzepatide in the HAVO pen presentation. Explore its dual-receptor mechanism and the safety information associated with the active ingredient.
Overview
HAVO Tirzepatide is presented as a pen for subcutaneous administration, with 60 mg in 3 ml according to the supplied packaging.
Mechanism & scientific context
Tirzepatide activates GIP and GLP-1 receptors, supporting glucose-dependent insulin secretion and influencing appetite.
Indications & evidence
Authorised tirzepatide medicines have indications for type 2 diabetes and weight management in specified populations. These authorisations do not validate the HAVO formulation.
Presentation & box contents
Pen presentation with a declared volume of 3 ml. The amount shown is the total content, not a dose per injection. Needle compatibility, dose settings and included accessories must be checked against the instructions supplied with the product.
Contraindications
The US Mounjaro label contraindicates use with personal or family medullary thyroid carcinoma, MEN2, or serious hypersensitivity to tirzepatide or excipients. These are reference-medicine restrictions, not a validated HAVO leaflet.
Precautions
Review pancreatitis, gallbladder disease, severe gastrointestinal disease, dehydration, retinopathy and hypoglycaemia risk with insulin or sulfonylureas. Discuss pregnancy, oral medicines and planned anaesthesia with the clinician. Nausea, vomiting and diarrhoea can occur. Seek urgent care for severe persistent abdominal pain or allergic symptoms.
Storage & handling
Keep refrigerated between 2°C and 8°C, as specified by HAVO for this presentation. Follow the product label for expiry and the period after first use. No room-temperature allowance or in-use shelf life has been established here. If frozen, damaged or exposed to temperatures outside this range, contact the laboratory before use.
Scientific information about an ingredient does not establish approval, efficacy or equivalence of this HAVO presentation. Consult the local product documentation and a qualified healthcare professional. This summary is not a prescribing guide.